Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nyxoah SA
NYXH | US
2.87
USD-0.10
-3.37%
NYXH | US
About Nyxoah SA
Sector
Healthcare
Industry
Medical Instruments & Supplies
Earnings date
30/06/2024
As of date
03/06/2026
Close
2.87
Open
2.91
High
2.93
Low
2.85
Nyxoah S.A. a medical technology company focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system a CE-Marked patient-centric and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert Belgium.
View LessNYXH | US
Risk
67.0
Sharpe
-1.09
Luna's Score
48/100
Recommendation
Hold
Luna says (NYXH | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
55.4%1 month
67.0%3 months
70.0%6 months
62.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.74
Debt to equity
0.11
Debt to assets
0.09
Ent. to EBITDA
-2.00
Ent. to rev.
55.40
PEG
-
Other Fundamentals
EBITDA
-46.63M
MarketCap
108.08M
MarketCap(USD)
108.08M
Div. yield
-
Op. margin
-1.73K
Erngs. growth
-
Rev. growth
-30.40
Ret. on equity
-36.94
Short ratio
5.35
Short perc.
0.45
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.38
Range1M
0.67
Range3M
1.32
Volumes: Market Activity
Rel. volume
0.46
Price X volume
53.84K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.00 | - | Cheaper |
| Ent. to Revenue | 55.40 | - | Expensive |
| PE Ratio | - | 47.18 | - |
| Price to Book | 2.74 | 5.71 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 70.02 | - | Riskier |
| Debt to Equity | 0.11 | 0.92 | Cheaper |
| Debt to Assets | 0.09 | 0.27 | Cheaper |
| Market Cap | 108.08M | - | Emerging |
